This paper reports the chemoenzymatic synthesis of an amylose‐grafted cellulose. A maltoheptaose was chemically introduced to the amine‐functionalized cellulose by reductive amination to produce the maltoheptaose‐grafted cellulose. Then, the phosphorylase‐catalyzed enzymatic polymerization of glucose 1‐phosphate from the graft‐chain ends on the cellulose derivative was performed, giving the amylose‐grafted cellulose. The obtained material is shown to form gels and films. The dry and wet cycles of the materials were repeated.
PZQ is the primary drug for treatment of schistosomiasis, but its efficiency is severely affected by its bitter taste. The main objective of this paper is the preparation of PMMA nanoparticles loaded with PZQ through in situ miniemulsion polymerizations and intended for oral formulations. Polymerizations are performed with an ultra turrax and a high‐pressure homogenizer. Obtained nanoparticles are analyzed by DSC, HPLC, DLS, GC, SEM, and PZQ dissolution profiles. Obtained results indicate the successful encapsulation of PZQ in all runs. Obtained data also show that the high‐pressure homogenizer leads to the best performance, allowing for preparation of stable latexes, with narrower particle size distributions and higher encapsulation efficiencies.
The antitumor activities of DOX‐loaded alginic acid/poly[2‐(diethylamino)ethyl methacrylate] (ALG‐PDEA) nanoparticles are evaluated both in vitro and in vivo. TEM imaging shows that the ALG‐PDEA NPs have a spherical morphology with a size of about 120 nm. CLSM observations reveal that the negatively charged ALG‐PDEA NPs can be taken up well by cells. In vivo NIR fluorescence imaging shows that the ALG‐PDEA NPs can passively target the tumor area because of the EPR effect in the H22 tumor‐bearing mouse. In vivo antitumor efficacy examinations indicate that DOX‐loaded ALG‐PDEA NPs have significantly superior efficacy in impeding tumor growth compared to free DOX and low toxicity to living mice.
Thiolated Pluronic (Plu‐SH) nanoparticles are developed as potential articulate, target‐specific anticancer‐drug carriers for intracellular drug release triggered by the difference in redox potential in tumor cells. The cores of the micelles are formed by the disulfide bonds of the functionalized Pluronic F127, when dissolved in an aqueous solution. The nanoparticles are 95.6 ± 18.6 nm in size, and 235.6 ± 63.7 nm after encapsulation of the hydrophobic drug molecules. The drug‐loaded micelles show effective stability in blood‐plasma conditions and the kinetics of micelle stability and drug release are shown. Paclitaxel‐loaded micelles display approximately 39% cell viability in A549 cells.
A novel amphiphilic and biodegradable polyelectrolyte DS‐CA is prepared by the esterification of DS with CA. DS‐CA can self‐assemble into stable nanoparticles in water. SOD can effectively associate with DS‐CA at pH = 5.0 by virtue of electrostatic and hydrophobic interactions. SOD release from the complex nanoparticles is slow at pH = 1.2. The release at pH = 7.4 PBS shows an extended behavior and is tunable by changing the weight ratio of SOD to DS‐CA as well as the CA substitution degree. Increasing the CA substitution degree of DS‐CA can significantly enhance the cellular uptake of the loaded SOD. This study demonstrates that the amphiphilic DS‐CA provides a promising strategy for oral delivery of protein/peptide drugs.
